Stocktwits on MSN
CTMX stock garners price target revisions after colorectal cancer trial data: Jefferies sees as much as 230% upside
Guggenheim also raised its price target on CytomX Therapeutics to $15 from $10 and kept a ‘Buy’ rating on the shares.
TrumpRx drug prices aren’t the world’s lowest, says a new report comparing Wegovy and more to Germany and other nations. Read more here.
Zacks Investment Research on MSN
PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
Pfizer PFE is one of the leading oncology drugmakers with a strong presence across breast, genitourinary, thoracic, gastrointestinal and blood cancers. The company has a well-established portfolio of ...
The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...
After a significant ruling from the Supreme Court of Appeal, prostate cancer patients in South Africa can continue to access the affordable generic drug Enzutrix, despite legal challenges from patent ...
The TrumpRx website claims to offer the best prices for medications. Here’s where Americans still pay more — and much more.
Pharmacy benefit managers act as middlemen between drugmakers, insurers, pharmacies and patients and are accused of selling marked-up medicine.
Strikes on Iran disrupt Gulf air cargo, forcing pharmaceutical companies to reroute medicines through Saudi Arabia, Oman, and Turkey, raising costs and cancer drug prices.
Pharmacy benefit managers (PBMs) have used market leverage to demand rebates, which can lead drug manufacturers to increase sticker prices.
Some hospitals in the Netherlands are paying up to €2,800 more than others for the same cancer medicines, according to research examining how oncology drugs are priced across European ...
Hospitals in the Netherlands are paying vastly different amounts for the same cancer medications, with some treatments ...
Price transparency compliance is often “in-form” rather than “in-spirit,” with many machine-readable files failing to provide complete, accurate, and usable drug pricing data. Reform priorities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results